The AmB content in the liposome formulations was determined by high-performance liquid chromatography (HPLC) [25 (link)]. Liposomes were ruptured by MeOH and CHCl3 (1:1) and the solution was then diluted 10-fold with MeOH. The liposomes were filtered through polytetrafluoroethylene (PTFE) syringe filters with 0.45-μm pore size Whatman® syringe filters. The chromatographic analyses were performed on a HPLC Agilent 1200 Infinity Series HPLC system (Agilent Technologies, Waldbronn, Germany), using a C18 analytical column (Waters; 250 × 4.6 mm, 5 µm). The mobile phase consisted of (A) MeOH containing 0.1% v/v trifluoroaceticacid and (B) water containing 0.1% v/v trifluoroaceticacid, with a gradient flow of 60–84% (A) over 9 min. The flow rate was 1 mL/min. (Model 1260 Quat Pump VL), sample injection volumes were 20 µL (Model 1260 ALS), and the detection wavelength was 390 nm.
Agilent 1200 infinity series hplc system
Manufactured by Agilent Technologies
Sourced in Germany
The Agilent 1200 Infinity Series HPLC system is a high-performance liquid chromatography (HPLC) instrument designed for analytical and preparative applications. It offers a modular design, allowing for customization to meet specific analytical requirements. The system is capable of performing various HPLC techniques, including reverse-phase, normal-phase, and ion-exchange chromatography.
Automatically generated - may contain errors
Lab products found in correlation
Xterra rp c18 column, by Waters Corporation (2 mentions)
Agilent 1290 infinity, by Agilent Technologies (2 mentions)
C18 analytical column, by Waters Corporation (1 mentions)
Model 1260 als, by Agilent Technologies (1 mentions)
Model 1260 quat pump vl, by Agilent Technologies (1 mentions)
Epicatechin, by Merck Group (1 mentions)
4 protocols using agilent 1200 infinity series hplc system
1
Quantifying Amphotericin B in Liposomes
2
Quantitative HPLC Analysis of Oxaliplatin Release
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HPLC analysis was performed using an Agilent 1200 Infinity Series HPLC system (Agilent Technologies, Waldbronn, Germany) to determine the % EE and in vitro oxaliplatin release from MVLs. Briefly, after necessary dilution with the mobile phase, 20 μL of each sample was injected by using an autosampler (Model 1260 ALS, Agilent Technologies, Waldbronn, Germany). The chromatographic analyses were performed through a XTerra™ RPC18 column (Waters, Milford, MA, USA; 300 × 3.9 × 5 μm) and detected at 254 nm using an HPLC-UV spectrometer (Agilent 1290 Infinity, Agilent Technologies, Waldbronn, Germany). The mobile phase consisted of a 30:70 (v/v) mixture of MeOH and 5-mM sodium-1 heptane sulfonate in water. A flow rate of 1 mL/min of the mobile phase (Model 1260 Quat Pump VL, Agilent Technologies, Waldbronn, Germany) was used.
3
HPLC-Based Oxaliplatin Release and Encapsulation Efficiency
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In vitro oxaliplatin release and % EE were determined by using HPLC Agilent 1200 Infinity Series HPLC system (Agilent Technologies, Waldbronn, Germany). Briefly, XTerra™ RPC18 column (particle size 5 μm, inside diameter 4.6 mm, and length 250 mm; Waters Corporation, Milford, MA, USA) at 210 nm using an HPLC-UV spectrometer (Agilent 1290 infinity). The mobile phase was a 20:80 mixture of ACN and deionized water and was set to a flow rate of 0.8 mL/min (Model 1260 Quat Pump VL). The samples were diluted as necessary, and 20 μL of each sample was injected using an autosampler (Model 1260 ALS).2.9. Statistical Analysis
In vitro percent (%) cumulative oxaliplatin release and in vivo pharmacokinetic study data are expressed as the means ± standard deviations. The t-test or two-sided RM ANOVA and Bonferroni test were applied to the analyses of the differences between the groups. A p value < 0.05 was considered as a statistically significant difference.
In vitro percent (%) cumulative oxaliplatin release and in vivo pharmacokinetic study data are expressed as the means ± standard deviations. The t-test or two-sided RM ANOVA and Bonferroni test were applied to the analyses of the differences between the groups. A p value < 0.05 was considered as a statistically significant difference.
4
Plasma Epicatechin Quantification Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Plasma samples were extracted by the method described by Spadafranca et al. [22 (link)]. Briefly, 20 μl vitamin C-EDTA (200 mg vitamin C and 1 mg EDTA in 1 ml 0.4 mol/l NaH2PO4) and 20 μl glucuronidase/sulfatase type II (Sigma, St. Louis, MO) were added to 200 μl plasma and incubated at 37°C for 45 minutes. Flavonoids were extracted by addition of 500 μl acetonitrile, and the mixture was centrifuged at 10,000 g for 5 minutes at room temperature. After centrifugation, the supernatant was removed, dried under nitrogen, and reconstituted in the aqueous HPLC mobile phase. After centrifugation, 50 μl supernatant was injected into the HPLC column for separation, detection, and analysis.
The HPLC analysis was performed using an HPLC system (Agilent 1200 Infinity Series HPLC system, Santa Clara, USA). Separations were carried out at a flow rate of 1.5 ml/min with an isocratic mobile phase of 85% Na2PO4 10 mol/l, pH 3, and 15% acetonitrile. Chromatograms were recorded at 279 nm, and plasma epicatechin identification was made by comparison of retention times with those of commercially available authentic (-)-epicatechin (Sigma, St. Louis, MO) through the same procedures as the plasma samples.
The HPLC analysis was performed using an HPLC system (Agilent 1200 Infinity Series HPLC system, Santa Clara, USA). Separations were carried out at a flow rate of 1.5 ml/min with an isocratic mobile phase of 85% Na2PO4 10 mol/l, pH 3, and 15% acetonitrile. Chromatograms were recorded at 279 nm, and plasma epicatechin identification was made by comparison of retention times with those of commercially available authentic (-)-epicatechin (Sigma, St. Louis, MO) through the same procedures as the plasma samples.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!